Pictet Asset Management (Switzerland)’s ImmunityBio IBRX Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$59.9K	Sell	21,556 -2,400,344	-99%	-$6.79M	﹤0.01%	1922
2023 Q1	$4.41M	Buy	2,421,900 +1,575,780	+186%	+$4.9M	0.01%	804
2022 Q4	$4.29M	Buy	846,120 +207,943	+33%	+$1.14M	0.01%	770
2022 Q3	$3.17M	Buy	638,177 +197,199	+45%	+$899K	﹤0.01%	831
2022 Q2	$1.64M	Buy	440,978 +28,437	+7%	+$114K	﹤0.01%	969
2022 Q1	$2.31M	Hold	412,541	–	–	﹤0.01%	947
2021 Q4	$2.51M	Buy	412,541 +101,307	+33%	+$761K	﹤0.01%	968
2021 Q3	$3.03M	Buy	+311,234	New	+$3.42M	﹤0.01%	930

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return

Allen Holding New York $1.01B AUM 14.43% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s IBRX Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) reduced its ImmunityBio (IBRX) stake by 99% in Q2 2023, selling an estimated $6.79M and leaving 21,556 shares worth $59.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1922.

Pictet Asset Management (Switzerland) first reported a position in IBRX in Q3 2021 and has held it in 8 quarters since. The position peaked at $4.41M in Q1 2023. 118 funds tracked by Wall St. Rank hold IBRX as of Q2 2023.

Pictet Asset Management (Switzerland) held 21,556 shares of ImmunityBio worth $59.9K as of Q2 2023.
Pictet Asset Management (Switzerland) sold 2,400,344 ImmunityBio shares in Q2 2023, an estimated $6.79M.
ImmunityBio made up ﹤0.01% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #1922 holding.
Pictet Asset Management (Switzerland) first reported a position in ImmunityBio in Q3 2021 and has held it in 8 quarters since.
Pictet Asset Management (Switzerland)'s ImmunityBio position peaked at $4.41M in Q1 2023.
118 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.